Caroline Deckmann Nicoletti

Caroline Deckmann Nicoletti

Auto-generated profile, based on publicly available information

Caroline Deckmann Nicoletti

Department of Pharmacy and Pharmaceutical Administration, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2022 in Brazilian Journal of Microbiology
Verified
Journal Article
Closed access
PDF file
LBLuana P. Borba-Santos
Luana P. Borba-Santos
CNCaroline Deckmann Nicoletti
Caroline Deckmann Nicoletti
TVTaissa Vila
Taissa Vila
PFPatricia Garcia Ferreira
Patricia Garcia Ferreira
CLCarlos Fernando Araújo Lima
Carlos Fernando Araújo Lima
SRSonia Rozental
Sonia Rozental

21 March 2020 in Journal of Bioenergetics and Biomembranes
Verified
Journal Article
Closed access
PDF file
CNCaroline Deckmann Nicoletti
Caroline Deckmann Nicoletti
AFAna Flávia Martins Faria
Ana Flávia Martins Faria
MQMarcella de Sá Haddad Queiroz
Marcella de Sá Haddad Queiroz
RGRaíssa Maria dos Santos Galvão
Raíssa Maria dos Santos Galvão
ASAndré Luis Almeida Souza
André Luis Almeida Souza
VFVitor Francisco Ferreira
Vitor Francisco Ferreira

14 September 2019 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
CMCaroline dos S. Moreira
Caroline dos S. Moreira
CNCaroline D. Nicoletti
Caroline D. Nicoletti
DPDaniel P. Pinheiro
Daniel P. Pinheiro
LMLeonardo G. C. de Moraes
Leonardo G. C. de Moraes
DFDebora O. Futuro
Debora O. Futuro
David da RochaDavid da Rocha
David da Rocha

1 July 2024 in Current Organic Chemistry
Verified
Journal Article
Closed access
PDF file
ACAlcione S. de Carvalho
Alcione S. de Carvalho
GFGabriel R.M. de Freitas
Gabriel R.M. de Freitas
CNCaroline D. Nicoletti
Caroline D. Nicoletti
FSFernando de C. da Silva
Fernando de C. da Silva
DFDébora O. Futuro
Débora O. Futuro
PFPATRICIA FERREIRA
PATRICIA FERREIRA
Sporotrichosis, recognized by the World Health Organization (WHO) as a neglected tropical disease and classified among significant fungal health concerns, remains both underestimated and underreported. There is a profound impact of sporotrichosis on public health, affecting both humans and domestic animals. The causative agents are fungi within the Sporothrix genus, primarily transmitted through traumatic exposure to contaminated soil, plants, decomposing materials, or through scratches from infected animals, notably cats. While sporotrichosis is a global concern, its prevalence is particularly noteworthy in tropical and subtropical regions. The limited treatment options for sporotrichosis, with itraconazole as the preferred choice, underscore the challenges posed by fungal infections. Issues such as toxicity and drug resistance further complicate effective management. Consequently, this review aims to elucidate key objectives: identification of novel synthetic compounds revealed in the literature, highlighting ongoing efforts to develop new treatments against sporotrichosis, examining promising anti-sporothrix natural products, and providing an overview of endeavors to repurpose approved drugs. The key findings from the study underscore the urgent need for diversified and effective drugs for the treatment of Sporotrichosis.

18 August 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
PFPATRICIA FERREIRA
PATRICIA FERREIRA
CNCaroline Deckmann Nicoletti
Caroline Deckmann Nicoletti
Vitor ferreiraVitor ferreira
Vitor ferreira
TLTácio de Mendonça Lima
Tácio de Mendonça Lima
Background: 3D printing is an advanced, computer-aided design (CAD)–guided, layer-by-layer manufacturing technology with strong potential for producing patient-specific drug products. Integrating AI with pharmaceutical 3D printing can accelerate formulation development, improve process robustness and quality, and enable efficient personalization across the preprinting, printing, and postprinting stages. However, evidence remains dispersed across technologies, dosage forms, and AI approaches, making it difficult to obtain a comprehensive understanding of current research and knowledge gaps. Objective: This scoping review protocol aims to map and characterize how AI has been applied to the formulation design, process optimization, and quality control of 3D printed drug products across the preprinting, printing, and postprinting stages. Methods: This review will follow the Joanna Briggs Institute (JBI) methodology and the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) checklist and guidelines for scoping reviews. The following databases and resources will be searched: MEDLINE (PubMed), Scopus, and Web of Science. Screening, data extraction, and data analysis will be conducted by 2 reviewers independently. Findings will be presented in summary tables and a narrative synthesis. Results: The protocol and search strategy were finalized in April 2026, and the review was registered on the Open Science Framework (OSF). Literature searches are scheduled to be conducted between May 2026 and June 2026, followed by title and abstract screening and full-text assessment between June 2026 and August 2026. Data extraction and narrative synthesis are expected to be completed by September 2026. The final scoping review is expected to be submitted for publication in the fourth quarter of 2026. Conclusions: This protocol outlines a scoping review to map the use of AI in the formulation design, process optimization, and quality control of 3D printed drug products, and summarize current research and identify areas for future investigation. Trial Registration: Open Science Framework 10.17605/OSF.IO/2R8ED; https://osf.io/2r8ed/overview International Registered Report Identifier (IRRID): PRR1-10.2196/98251

14 April 2026 in JMIR Preprints
Verified
Preprint
Open access
PFPATRICIA FERREIRA
PATRICIA FERREIRA
CNCaroline Deckmann Nicoletti
Caroline Deckmann Nicoletti
Vitor ferreiraVitor ferreira
Vitor ferreira
TLTácio de Mendonça Lima
Tácio de Mendonça Lima
BACKGROUND 3D printing is an advanced, computer-aided design (CAD)–guided, layer-by-layer manufacturing technology with strong potential for producing patient-specific drug products. Integrating AI with pharmaceutical 3D printing can accelerate formulation development, improve process robustness and quality, and enable efficient personalization across the preprinting, printing, and postprinting stages. However, evidence remains dispersed across technologies, dosage forms, and AI approaches, making it difficult to obtain a comprehensive understanding of current research and knowledge gaps. OBJECTIVE This scoping review protocol aims to map and characterize how AI has been applied to the formulation design, process optimization, and quality control of 3D printed drug products across the preprinting, printing, and postprinting stages. METHODS This review will follow the Joanna Briggs Institute (JBI) methodology and the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) checklist and guidelines for scoping reviews. The following databases and resources will be searched: MEDLINE (PubMed), Scopus, and Web of Science. Screening, data extraction, and data analysis will be conducted by 2 reviewers independently. Findings will be presented in summary tables and a narrative synthesis. RESULTS The protocol and search strategy were finalized in April 2026, and the review was registered on the Open Science Framework (OSF). Literature searches are scheduled to be conducted between May 2026 and June 2026, followed by title and abstract screening and full-text assessment between June 2026 and August 2026. Data extraction and narrative synthesis are expected to be completed by September 2026. The final scoping review is expected to be submitted for publication in the fourth quarter of 2026. CONCLUSIONS This protocol outlines a scoping review to map the use of AI in the formulation design, process optimization, and quality control of 3D printed drug products, and summarize current research and identify areas for future investigation. CLINICALTRIAL Open Science Framework 10.17605/OSF.IO/2R8ED; https://osf.io/2r8ed/overview INTERNATIONAL REGISTERED REPORT PRR1-10.2196/98251